

# Structure of a G protein-coupled receptor with GRK2 and a biased ligand

H. Eric Xu (✉ [eric.xu@simm.ac.cn](mailto:eric.xu@simm.ac.cn))

Shanghai Institute of Materia Medica (SIMM) <https://orcid.org/0000-0002-6829-8144>

Jia Duan

Shanghai Institute of Materia Medica (SIMM)

Heng Liu

Shanghai Institute of Materia Medica (SIMM)

Yujie Ji

Shanghai Institute of Materia Medica (SIMM)

Qingning Yuan

Shanghai Institute of Materia Medica (SIMM)

Xinzhu Li

Shanghai Institute of Materia Medica (SIMM)

Kai Wu

Shanghai Institute of Materia Medica (SIMM)

Tianyu Gao

Shanghai Institute of Materia Medica (SIMM)

Shengnan Zhu

Macau University of Science and Technology

Yi Jiang

Shanghai Institute of Materia Medica (SIMM)

Wanchao Yin

Shanghai Institute of Materia Medica <https://orcid.org/0000-0002-6889-4907>

---

Biological Sciences - Article

Keywords:

Posted Date: October 18th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-2149634/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---



1 **Structure of a G protein-coupled receptor with GRK2 and a biased ligand**

2  
3 Jia Duan<sup>1,\*,#</sup>, Heng Liu<sup>1,\*</sup>, Yujie Ji<sup>1,2,\*</sup>, Qingning Yuan<sup>1</sup>, Xinzhu Li<sup>1,3</sup>, Kai Wu<sup>1</sup>, Tianyu  
4 Gao<sup>1,4</sup>, Shengnan Zhu<sup>5</sup>, Wanchao Yin<sup>1</sup>, Yi Jiang<sup>6</sup>, H. Eric Xu<sup>1,2,4,#</sup>

5  
6 <sup>1</sup>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,  
7 Chinese Academy of Sciences, Shanghai 201203, China

8 <sup>2</sup>University of Chinese Academy of Sciences, Beijing 100049, China

9 <sup>3</sup>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing,  
10 210023 China

11 <sup>4</sup>School of Life Science and Technology, ShanghaiTech University, Shanghai 201210,  
12 China

13 <sup>5</sup>School of Pharmacy, Macau University of Science and Technology, Macau 999078,  
14 China

15 <sup>6</sup>Lingang Laboratory, Shanghai 200031, China

16 \*These authors contributed equally.

17 **#Co-corresponding authors:**

18 H.E.X., email: [eric.xu@simm.ac.cn](mailto:eric.xu@simm.ac.cn)

19 J.D., email: [duanjia@simm.ac.cn](mailto:duanjia@simm.ac.cn)

20

21 **Abstract**

22 **Phosphorylation of G protein-coupled receptors (GPCR) by GPCR kinases**  
23 **(GRKs) desensitizes G protein signaling and promotes arrestin signaling, which**  
24 **is also modulated by biased ligands<sup>1-6</sup>. Molecular assembly of GRKs to GPCRs**  
25 **and the basis of GRK-mediated biased signaling remain largely unknown due to**  
26 **the weak GPCR-GRK interactions. Here we report the complex structure of**  
27 **neurotensin receptor 1 (NTSR1) bound to GRK2, Gαq, and an arrestin-biased**  
28 **ligand, SBI-553<sup>7</sup>, at a resolution of 2.92 Å. The high-quality density map reveals**  
29 **the clear arrangement of the intact GRK2 with the receptor, with the N-terminal**  
30 **helix of GRK2 docking into the open cytoplasmic pocket formed by the outward**  
31 **movement of the receptor TM6, analogous of the binding of G protein to the**  
32 **receptor. Strikingly, the arrestin-biased ligand is found at the interface between**  
33 **GRK2 and NTSR1 to enhance GRK2 binding. The binding mode of the biased**  
34 **ligand is compatible with arrestin binding but is clashed with the binding of a G**  
35 **protein, thus provide an unambiguous mechanism for its arrestin-biased**  
36 **signaling capability. Together, our structure provides a solid model for**  
37 **understanding the details of GPCR-GRK interactions and biased signaling.**

38

39 GPCRs comprise the largest family of cell surface receptors whose signaling is  
40 primarily mediated by two types of downstream effectors: G-proteins and arrestins.  
41 The switch of GPCR signaling from G-protein pathways to arrestin pathways is  
42 controlled by a small family of GPCR kinases, GRKs, which phosphorylate either the  
43 receptor C-terminal tail or the third intracellular loop (ICL3)<sup>1-3</sup>. Phosphorylation of  
44 GPCRs promotes recruitment of arrestin, which blocks G-protein binding and  
45 desensitizes G-protein signaling<sup>3</sup>. Because drugs that selectively activate either G-  
46 protein pathways or arrestin pathways (biased signaling) are proposed to have better  
47 therapeutic and safety index<sup>4,5</sup>, the mechanism of GPCR biased signaling has been a  
48 subject of intensive research over the past two decades.

49

50 GRK2, along with GRK1, are the prototypes of GRKs that belong to the AGC family of  
51 serine/threonine kinases<sup>8-10</sup>. There are seven GRKs, which can be grouped into the  
52 rhodopsin kinase subfamily (GRK1 and GRK7), the  $\beta$ -adrenergic receptor kinase  
53 subfamily (GRK2 and GRK3), and the GRK4 subfamily (GRK4, GRK5 and GRK6)<sup>9</sup>. All  
54 GRKs share conserved sequence features and structural arrangements<sup>11</sup>. At the N-  
55 terminus is a conserved segment that formed a helix in the active GRK structures,  
56 followed by the first eight helices of a regulatory G-protein signaling homology domain  
57 (RHD)<sup>10,12</sup>. The kinase domain (KD) is inserted into a loop between helices 8 and 9 of  
58 RHD, a conserved domain of a nine-helix bundle found in regulatory G-protein  
59 signaling proteins<sup>13</sup>. Following the kinase domain and helix 9 of RHD are the less  
60 conserved C-terminal GRK domains, which are mainly responsible for membrane  
61 binding<sup>14</sup>. In the case of GRK2, its C-terminus contains a pleckstrin homology domain  
62 (PHD) that interacts with G $\beta\gamma$  subunits of G protein<sup>15</sup>. The RHD of GRK2 also interacts  
63 with G $\alpha_q$  when it is in complex with GTP<sup>16</sup>. The binding of both G $\alpha_q$  and G $\beta\gamma$  subunits  
64 to GRK2 facilitates its membrane association<sup>15,16</sup>.

65

66 As GPCR signal transducers like G proteins and arrestins, GRKs are rest at the basal  
67 state, and can be recruited and activated by active GPCRs<sup>3</sup>. The molecular basis of  
68 how GPCR signal transducers recognize and regulate GPCR signaling has been a  
69 research focus of GPCR structural biology<sup>14,17-21</sup>. Structures of many GPCR-G protein  
70 complexes and GPCR-arrestin complexes have been solved, which reveal that both G  
71 proteins and arrestins recognize the open cytoplasmic pocket induced by the outward  
72 movement of TM6 in the activated GPCRs<sup>19,20,22-25</sup>. Due to much weaker interactions  
73 between GPCR and GRKs, high resolution structure of a GPCR-GRK complex is  
74 technically challenging. A structure of rhodopsin in complex with GRK1 has provided a  
75 breakthrough view of the overall assembly of GRK1 with rhodopsin via its N-terminal  
76 helix<sup>18</sup>. However, the relatively low resolution of the structure lacks the density for the  
77 conserved RHD domain of GRK1 and limits the detailed understanding of rhodopsin-  
78 GRK1 interactions and GRK1 activation by the active rhodopsin.

79

80 Neurotensin receptor 1 (NTSR1) is a class A GPCR that is regulated by an endogenous  
81 peptide ligand, neurotensin (NTS)<sup>26</sup>. Up on activation, NTSR1 couples to various signal  
82 effectors, including several subtypes of G proteins, GRKs, and arrestins, to mediate  
83 neurotransmission and neuromodulation in the central nervous system<sup>26-28</sup>. Because  
84 of its diverse physiological roles, NTSR1 has been proposed as a drug target for  
85 addiction, obesity, analgesia, cancer, Parkinson's disease, and schizophrenia<sup>7</sup>.  
86 Structures of NTSR1 in complex with Gi or beta-arrestin have been determined by  
87 cryo-electron microscopy (cryo-EM)<sup>22,23,29</sup>. Notably, SBI-553, a  $\beta$ -arrestin-biased  
88 allosteric ligand of NTSR1 that antagonizes G-protein signaling, selectively reduces  
89 addictive behaviors without the unwanted side effects of hypotension, hypothermia,  
90 and motor impairment, which are typically associated with balanced agonism of  
91 NTSR1 induced by neurotensin<sup>7</sup>. However, the structural basis of  $\beta$ -arrestin-biased  
92 agonism of SBI-553 remains unknown. In this paper, we report the structure of NTSR1  
93 bound to NTS, GRK2, G $\alpha$ q, and SBI-553 at a resolution of 2.92 Å, which reveals  
94 detailed interactions between NTSR1 and GRK2, and provides a molecular  
95 explanation for the  $\beta$ -arrestin-biased agonism of SBI-553.

96

### 97 **Complex assembly and structure determination**

98 To identify a stable GPCR–GRK2 complex, we used Tango assays<sup>30</sup> to screen various  
99 members of class A GPCRs, and NTSR1 turned out to be one of the strongest  
100 receptors that interact with GRK2 (**Extended Data Fig. 1a**). Addition of SBI-553 further  
101 increased NTSR1-GRK2 interaction (**Fig. 1a**). The presence of SBI-553 enhanced  
102 potency and efficacy of NTS to promote GRK2 recruitment to NTSR1 (**Fig. 1b**). Co-  
103 expression of NTSR1 with GRK2 as well as G $\alpha$ q and G $\beta$  $\gamma$  formed a complex that could  
104 be purified to homogeneity but it was unstable (**Extended Data Fig. 1b**). We introduced  
105 the NanoBiT tethering strategy<sup>31,32</sup> to stabilize the complex by fusing LgBiT to the C-  
106 terminus of NTSR1 and HiBiT to the C-terminus of GRK2. The purification of the above  
107 complex showed a sub-stoichiometry ratio of the G $\beta$  $\gamma$  subunit (**Extended Data Fig. 1c**),

108 indicating instable association of the G $\beta\gamma$  subunit with the rest of the complex. We thus  
109 omitted the G $\beta\gamma$  subunit from the final complex assembly, which was further stabilized  
110 by chemical crosslinking with BS<sub>3</sub> for cryo-EM studies (Extended Data Fig. 1d-f).

111

112 A total of 57,477 film images were collected, which yield ~40 million initial particles.  
113 Further 2D and 3D classifications generate two maps at resolutions of 2.92 Å and 3.09  
114 Å (Extended Data Fig. 2). The data and structure statistics are summarized in  
115 Extended Data Table 1. Both maps were sufficiently clear to place NTSR1, NTS, GRK2,  
116 G $\alpha_q$ , and the bound SBI-553, staurosporine, and GDP·AlF<sub>4</sub><sup>-</sup>·Mg<sup>2+</sup> (Fig. 1c, 1d and  
117 Extended Data Fig. 2, 3). Comparison of these two complexes reveals that they have  
118 very similar NTSR1 structure but a swing of GRK2 of ~5-6 Å related to NTSR1  
119 (Extended Data Fig. 4), suggesting the dynamics of the NTSR1-GRK2 complex  
120 assembly. 3D variability analysis (3DVA) of the two cryo-EM maps also reveal dynamic  
121 swing of GRK2 around NTSR1, especially the G $\alpha_q$  subunit and the relative positions  
122 between the RHD and kinase domain (Extended Data movie). Complex 1 (Figure 1c)  
123 has higher resolution and is thus used for detailed analysis below.

124

### 125 **Structure of NTSR1-GRK2-SBI-553 complex**

126 Within the complex structure, NTSR1 resembles the NTSR1 structure in complex with  
127 Gi and  $\beta$ -arrestin<sup>22,23,29</sup> (Fig. 2a), with an overall RMSD less than 1.0 Å for the entire  
128 C $\alpha$  atoms of NTSR1. Compared to the inactive NTSR1 structure, conformational  
129 changes mainly occurred at cytoplasmic ends of TM5 (4.5 Å shift), TM6 (11.3 Å shift)  
130 and TM7 (1.7 Å shift), consistent with an active conformation of NTSR1 (Fig. 2a).

131

132 At the extracellular side, NTS, the peptide ligand, is fit into the top-central TMD pocket  
133 (Fig. 2b). At the intracellular side, SBI-553 is found at the bottom-central cytoplasmic  
134 pocket, Underneath SBI-553 is the N-terminal helix of GRK2, which docks into the  
135 open cytoplasmic pocket. The overall structure of NTSR1-GRK2 complex is similar to  
136 the rhodopsin-GRK1 complex<sup>18</sup> (Fig. 2c), however, the position of the N-terminal helix

137 of GRK2 is shift by as much as 8.0 Å relative to the N-terminal helix of GRK1 (Fig. 2c).  
138 Correspondingly, the whole kinase domain of GRK2 is shift by as much as 7-8 Å from  
139 the GRK1 kinase domain (Fig. 2c).

140

141 Compared to the partial GRK1 structure in the rhodopsin-GRK1 complex, GRK2 from  
142 the NTSR1-GRK2 complex has nearly complete structure with RH and PH domains  
143 clearly defined in the structure (Fig. 2c). In the structure, Gαq is bound to the RHD of  
144 GRK2 (Fig. 2d). Comparing the GRK2 structure from the NTSR1 complex to the crystal  
145 structure of GRK2 from the complex with Gαq and Gβγ reveals three major differences  
146 as below<sup>16</sup> (Extended Data Fig. 5). The GRK2 structure from the NTSR1 complex  
147 contains a N-terminal helix that is packed onto the kinase domain (Extended Data Fig.  
148 5), has a breakage in the ionic lock between its RHD from the KD, and adopts a closed  
149 conformation in its kinase domain that is in the active state (Extended Data Fig. 5). In  
150 contrast, the GRK2 crystal structure from the complex with Gαq and Gβγ does not  
151 have the N-terminal helix, contains the ionic lock between its RHD and the KD as seen  
152 in the GRK5 structure<sup>14,33</sup>, and adopts an open conformation in its kinase domain,  
153 resembling the inactive state (Extended Data Fig. 5).

154

155 The overall arrangement of the NTSR1-GRK2 complex also present possible  
156 association of GRK2 with the membrane lipid layer (Fig. 2d). Alignment of H8 of NTSR1  
157 with the membrane layer reveals that the C-terminal tip of helix 9 from RHD, the loop  
158 between β-strands 1 and 2, and the loop between β-strands 5 and 6 from PHD are in  
159 close contact with the membrane layer (Fig. 2d, Extended Data Fig. 6). Additional  
160 binding of GRK2 to the membrane layer could come from lipid modifications in the Gα  
161 and Gγ subunits (Fig. 2d). Modeling of the Gβγ subunit into the NTSR1-GRK2 structure  
162 suggest that the C-terminal lipid modification of the Gγ subunit is also close to the  
163 membrane layer (Fig. 2d). In addition, superposition of GRK5 to GRK2 in the NTSR1-  
164 GRK2 complex reveals that the N-terminal lipid binding domain (NLBD) and C-terminal  
165 lipid binding domain (CLBD) of GRK5 are near the membrane layer (Fig. 2d, Extended



166 **Data Fig. 6**), consistent with their roles in lipid binding<sup>14</sup>.

167

### 168 **The GRK2-NTSR1 interface**

169 The GRK2-NTSR1 interface is at the center of the complex, which has relatively high  
170 resolution at ~2.5 Å (**Extended Data Fig. 2c, 2d**), thus the density map is clear for  
171 interface residues, which reveals detailed intermolecular interactions between GRK2  
172 and NTSR1 at the residue-specific levels (**Fig. 3**). The GRK2-NTSR1 complex has  
173 one major interface comprised by the N-terminal helix of GRK2, which inserts into the  
174 open TM6 pocket (**Fig. 3a, 3b**), and one minor interface comprised by ICL2 of NTSR1  
175 that interact with the loop between the N-terminal helix and the RHD (**Fig. 3c**).

176

177 At the major interface, five hydrophobic residues (L4, V7, L8, V11, and M15) from the  
178 N-terminal helix of GRK2 form an extended hydrophobic patch, which is packed  
179 against a hydrophobic pocket formed by hydrophobic residues from TM5, TM6, and  
180 TM7 (L263<sup>5.65</sup>, M266<sup>5.68</sup>, A297<sup>6.29</sup>, L298<sup>6.30</sup>, G301<sup>6.33</sup>, and V367<sup>7.56</sup>) (**Fig. 3a**). In addition,  
181 the carboxylate side chain of D3 forms a network of hydrogen bonds with the main  
182 chain amine groups of A369<sup>8.48</sup> and N370<sup>8.49</sup>, and the side chains of S368<sup>8.47</sup> and  
183 N370<sup>8.49</sup>. R294<sup>6.26</sup> also forms a direct hydrogen bond with the main chain carbonyl from  
184 G475 of GRK2 (**Fig. 3b**). These additional hydrogen bonds may also help to stabilize  
185 the N-terminal helix of GRK2 in the cytoplasmic pocket. At the ICL2 minor interface,  
186 F174 is packed against the main chain of N189 from GRK2, K177 forms a hydrogen  
187 bond with the main chain carbonyl of F191 from the GRK2 kinase domain, and T178  
188 forms a hydrogen bond with the side chain of N189 (**Fig. 3c**). The total buried surface  
189 area between GRK2 and NTSR1 is 746 Å<sup>2</sup>, which is considerably smaller than the  
190 NTSR1-Gi interface of 1197 Å<sup>2</sup>, consistent with the relatively weak NTSR1-GRK2  
191 interactions.

192

### 193 **The basis of SBI-553 biased agonism**

194 SBI-553 is an arrestin-biased PAM ligand that specifically blocks G protein signaling

195 but enhances arrestin signaling<sup>7</sup>. The high-quality density map clearly defines the  
196 binding mode of SBI-553 (Fig. 4), which adopts an inverted T-shape configuration and  
197 binds to the interface between NTSR1 and GRK2 (Fig. 4a, 4b). In the structure, SBI-  
198 553 forms extensive interactions with both receptor and GRK2 as summarized in  
199 Extended Data Table 2. Specifically, with the receptor, SBI-553 form predominately  
200 hydrophobic interactions with residues from TM2, TM3, TM5, TM6, TM7, and H8 (Fig.  
201 4c, 4d). With GRK2, SBI-553 forms direct interactions with L4, E5, and L8 from the N-  
202 terminal helix (Fig. 4d), consistent with the enhanced binding of GRK2 to NTSR1 by  
203 SBI-553 (Fig. 1a, 1b).

204

205 The binding site of SBI-553 is unique and unexpected, which has not been observed  
206 in any GPCR structures determined to date<sup>34,35</sup>. Structure superposition of NTSR1 from  
207 its Gi complex onto the NTSR1-GRK2 structure reveal that the  $\alpha 5$  helix from the G  
208 proteins occupies roughly the same space as occupied by the N-terminal helix of GRK2  
209 (Extended Data Fig. 7). However, the  $\alpha 5$  helix from the  $G_{\alpha i}$  is up-shift by as much as  
210 8.0 Å into the TMD pocket related to the N-terminal helix of GRK2 (Extended Data Fig.  
211 7). In this orientation, the  $\alpha 5$  helix from the  $G_{\alpha i}$  would clash directly with the bound SBI-  
212 553 (Fig. 4e), thus providing a direct explanation for inhibition of G protein signaling by  
213 SBI-553. Importantly, structural superposition of NTSR1 from its arrestin complex  
214 reveals that the binding of SBI-553 would be compatible with arrestin binding to NTSR1  
215 (Fig. 4f), consistent with its arrestin-biased signaling property.

216

### 217 **Universal features of GPCR-GRK interactions**

218 In this paper, we have determined the structure of NTSR1 in complex with GRK2 and  
219 SBI-553 at a resolution of 2.92 Å, with the interface region approaching to 2.5 Å  
220 (Extended Data Fig. 2c, 2d). The relatively high resolution of the structure provides a  
221 clear binding mode of GRK2 and SBI-553 to NTSR1 as well as the mode of GRK2  
222 membrane association. The primary binding site of GRK2 at NTSR1 is overlapped with  
223 the NTSR1 Gi binding site comprised by TM6, TM7 and H8, which structural features

224 are highly similar in the active structures of various GPCRs (Extended Data Fig. 8),  
225 thus providing a basis for GRK2's capability to interact with many different GPCRs.

226

227 In addition, the binding site of GRK2 at NTSR1 is the same as the GRK1 binding site  
228 in rhodopsin (Fig. 2c). In our structure, GRK2 has nearly complete structure with clear  
229 definition of many flexible regions, including the RHD and the active site tether (AST)  
230 loop, which tether the kinase domain in the active conformation. The residues from the  
231 N-terminal helix of GRK2 that interact with NTSR1 are highly conserved in all GRKs,  
232 suggesting the binding mode of GRK2 is a universal feature for all GRKs (Extended  
233 Data Fig. 6).

234

235 Finally, our structure reveals an unexpected binding mode of SBI-553, which is docked  
236 at the interface between GRK2 and NTSR1, consistent with its ability to enhance GRK2  
237 binding to NTSR1 (Fig. 1a, 1b, 2b). The binding of SBI-553 is compatible with arrestin  
238 binding but would clash with G proteins (Fig. 4e, 4f), thus providing a direct mechanism  
239 for its arrestin-biased signaling capability. Together, our structure provides a solid  
240 model (Fig. 5) for understanding the details of GPCR-GRK interactions and biased  
241 signaling, and a basis for designing arrestin-biased ligands for NTSR1 and possibly  
242 other GPCRs.

243

244

245 **Method**

246 **Constructs**

247 Human NTSR1 (residues 1-418) was codon-optimized for Sf9 expression and cloned  
248 into a modified pFastBac vector, which contains an N-terminal hemagglutinin (HA)  
249 signal peptide followed by a flag tag and a b562RIL (BRIL) epitope before the receptor.  
250 To improve the complex homogeneity and stability, the NanoBiT tethering strategy was  
251 applied by fusing a LgBiT subunit (Promega) at the receptor C-terminus after a  
252 GSSGGSGGGG linker<sup>31,32</sup>. Bovine GRK2 was cloned with a C-terminal  
253 GSSGGSGGGG linker followed by the HiBiT (peptide86) subunit<sup>32</sup>. Additionally, three  
254 mutations (A292P, R295I and S455D) were also incorporated into GRK2 by site-  
255 directed mutagenesis to enhance the affinity between GRK2 and Fab6<sup>18</sup>. Gαq  
256 construct was modified into a pFastBac vector. And the native N terminus (residues 1-  
257 28) of Gαq was replaced with Gαi1 to facilitate the expression of Gαq<sup>16</sup>.

258

259 **Expression and purification of NTSR1-GRK2-Gαq complex**

260 NTSR1-LgBiT, Gαq, GRK2-HiBiT and Ric8a (a gift from Brian Kobilka) were co-  
261 expressed in Sf9 insect cells (Invitrogen) using the Bac-to-Bac baculovirus expression  
262 system (ThermoFisher). Cell pellets were thawed and lysed in 20 mM HEPES, pH 7.4,  
263 100 mM NaCl, 10% glycerol, 10 mM MgCl<sub>2</sub>, 10 mM NaF and 30 μM AlCl<sub>3</sub> supplemented  
264 with Protease Inhibitor Cocktail, EDTA-Free (TargetMol). The NTSR1-GRK2-Gαq  
265 complex was formed in membranes by the addition of 10 μM NTS (Genscript), 10 μM  
266 satursporine, 10 μM SBI-553 (TargetMol) and 50 μM GDP. The suspension was  
267 incubated for 0.5 h at room temperature before centrifugation at 80,000 × g for 30 min.  
268 The membrane was then resuspended with the same buffer and solubilized using 0.5%  
269 (w/v) n-dodecyl β-D-maltoside (DDM, Anatrace), 0.1% (w/v) cholesterol hemisuccinate  
270 (CHS, Anatrace) for 2 h at 4 °C. The supernatant was collected by centrifugation at  
271 80,000 × g for 40 min and then incubated with G1 anti-Flag affinity resin (Genscript)  
272 for 2 h at 4 °C. After batch binding, the resin was loaded into a plastic gravity flow  
273 column and washed with 20 column volumes of 20 mM HEPES, pH 7.4, 100 mM NaCl,

274 10% glycerol, 10 mM MgCl<sub>2</sub>, 10 mM NaF, 30 μM AlCl<sub>3</sub>, 10 μM NTS, 10 μM  
275 saturosporine, 10 μM SBI-553 and 50 μM GDP, 0.01% (w/v) DDM, 0.002%(w/v) CHS,  
276 and 0.05%(w/v) digitonin, further eluted with 10 column volumes of the same buffer  
277 plus 0.2 mg/mL Flag peptide. The complex was then concentrated using an Amicon  
278 Ultra Centrifugal Filter (MWCO 100 kDa) and injected onto a Superose 6 Increase  
279 10/300 GL column (GE Healthcare) equilibrated in the buffer containing 20 mM HEPES,  
280 pH 7.4, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 mM NaF, 30 μM AlCl<sub>3</sub>, 10 μM NTS, 10 μM  
281 saturosporine, 5 μM SBI-553, 50 μM GDP, and 0.03% (w/v) digitonin. To stabilize the  
282 NTSR1-GRK2-Gαq complex, the peak fractions were collected and crosslinked using  
283 0.01 mM BS<sub>3</sub> for 0.5 h at room temperature, stopped crosslinking by addition of 80 mM  
284 of glycine, and then concentrated to approximately 10 mg/ml for cryo EM analysis.

285

#### 286 **Cryo-EM grid preparation and data collection**

287 For the preparation of cryo-EM grids, 3 μL of the purified protein at 10 mg/mL were  
288 applied onto a glow-discharged holey carbon grid (CryoMatrix Amorphous alloy film  
289 R1.2/1.3, 300 mesh). Grids were plunge-frozen in liquid ethane using Vitrobot Mark IV  
290 (Thermo Fischer Scientific). Frozen grids were transferred to liquid nitrogen and stored  
291 for data acquisition. Cryo-EM imaging of the complex was performed on a Titan Krios  
292 at 300 kV in the Advanced Center for Electron Microscopy at Shanghai Institute of  
293 Materia Medica, Chinese Academy of Sciences (Shanghai China).

294

295 A total of 57,477 movies for the NTSR1-GRK2-Gαq complex were collected by a Gatan  
296 K3 Summit direct electron detector with a Gatan energy filter (operated with a slit width  
297 of 20 eV) (GIF) at a pixel size of 0.824 Å using the EPU software. The micrographs  
298 were recorded in counting mode with a defocus ranging from -1.2 to -2.2 μm. The total  
299 exposure time was 3.33 s with a dose of 50 electrons, and intermediate frames were  
300 recorded in 0.104 s intervals, resulting in a total of 36 frames per micrograph.

301

#### 302 **Image processing and map construction**

303 A total of 57,477 dose-fractioned movies were used for correction of beam-induced  
304 movement using a dose-weighting scheme in MotionCor2<sup>36</sup> and their contrast transfer  
305 function parameters were estimated by Patch CTF estimation in CryoSPARC<sup>37</sup>. For  
306 the NTSR1-GRK2-Gαq complex, particle selection was performed by blob picking  
307 using CryoSPARC<sup>37</sup>, and 40,940,867 particles were extracted and further subjected to  
308 an initial reference-free 2D classification. Interactive 2D and 3D classifications were  
309 performed to discard poorly defined particles, and 1,149,932 particles were retained.  
310 These particles were divided into 6 subclasses using Ab-initial model and hetero-  
311 refinement, resulting in two subsets with complete NTSR1-GRK2-Gαq complex. Two  
312 maps from the two subsets showed slightly difference especially relative position of  
313 GRK2 and Gαq. We merged the two subsets, and performed another round of Ab-  
314 initial model and hetero-refinement to remove particles without clear NTSR1-GRK2-  
315 Gαq complex. In the 5 subclasses, two well-defined subsets, containing 287,853  
316 particles and 216,282 particles, respectively, were subsequently subjected to non-  
317 uniform refinement in CryoSPARC<sup>37</sup>, generated two different maps with global  
318 resolution of 2.92 Å and 3.09 Å. Resolution was estimated in the presence of a soft  
319 solvent mask and based on the gold standard Fourier shell correlation (FSC) 0.143  
320 criterion. Local resolution was estimated in cryoSPARC<sup>37</sup> using default parameters.  
321 Unless indicated otherwise, the maps shown in figures were sharpened with B factors  
322 estimated in the nonuniform refinement.

323

324 To analyze the flexibility of the NTSR1-GRK2-Gαq complex, we performed cryoSPARC  
325 3D variability analysis (3DVA)<sup>38</sup>. The 3DVA was performed with mask on the complex,  
326 generated from non-uniform refinement. The 3DVA was analyzed across three  
327 principal components that estimated the most common motions. One of the  
328 components showed pronounced motion between GRK2 and Gαq and the movie that  
329 consisted of 20 volume frame data were presented by Chimera (v1.4) in the **Extended**  
330 **Data movie**.

331

332 **Model building and refinement**

333 For the NTSR1-GRK2-Gαq complexes, the AlphaFold model of NTSR1 and the  
334 structure of G Protein-Coupled Receptor Kinase 2 in Complex with Gαq and Gβγ  
335 Subunits (PDB code: 2BCJ), were used as the start for model rebuilding and  
336 refinement against the electron microscopy map. The model was docked into the EM  
337 density map using Chimera<sup>39</sup>, followed by iterative manual adjustment and rebuilding  
338 in COOT<sup>40</sup> and ISOLDE<sup>41</sup>. Real space and reciprocal space refinements were  
339 performed using Phenix<sup>42</sup> programs with secondary structure and geometry restraints.  
340 The final refinement statistics were validated using the module “comprehensive  
341 validation (cryo-EM)” in Phenix<sup>42</sup>. The final refinement statistics are provided in  
342 **Extended Data Table 1**. Structure figures were prepared in ChimeraX<sup>43</sup> and PyMOL  
343 (<https://pymol.org/2/>).

344

345 **Calculation of NTSR1-Gi protein and NTSR1-GRK2 interface area**

346 NTSR1-GRK2-Gαq complex and NTSR1-Gi protein complex (PDB ID: 6OS9) were  
347 used for the calculation of NTSR1-GRK2, NTSR1-Gi interface areas respectively,  
348 using PDBePISA web server ([PDBe < PISA < EMBL-EBI](https://www.ebi.ac.uk/pdbe/entry/pisa/)). During the process, NTSR1-  
349 GRK2-Gαq complex and NTSR1-G protein complex were uploaded, and the  
350 Accessible surface area (ASA) calculations are based on finite element analysis  
351 through the “interface” module.

352

353 **NanoBiT assay for GRK2 recruitment**

354 The full-length NTSR1 (1–418) was cloned into pBiT1.1 vector (Invitrogen) with a  
355 FLAG tag at its N-terminus and LgBiT at its C-terminus. Bovine GRK2 (residues 1-689)  
356 was cloned into pBiT2.1 vector (Invitrogen) with a modified SmBiT (peptide104:  
357 MVEGYRLFEEKIS)<sup>31</sup> and a GSSGGGGSGGGGSSG linker at its N-terminus. AD293  
358 cells were cultured in DMEM/high Glucose (GE healthcare) supplemented with 10%  
359 (w/v) FBS (Gemini). Cells were maintained at 37 °C in a 5% CO<sub>2</sub> incubator with  
360 300,000 cells per well in a 6-well plate. Cells were grown overnight and then

361 transfected with 1.5 µg NTSR1 and 1.5 µg GRK2 constructs by FuGENE® HD  
362 transfection reagent in each well for 24 h. Cells were harvested and re-suspended in  
363 Hanks' balanced salt solution buffer (HBSS) at a density of  $5 \times 10^5$  cells/ml. The cell  
364 suspension was seeded in a 384-well plate at a volume of 10 µl per well, followed by  
365 10 µl HBSS or 10 µl HBSS containing 1 µM SBI-553, 10 µl HBSS containing different  
366 concentrations of NTS, and another 10 µl the NanoLuc substrate (furimazine, 1:25  
367 dilution, Promega) diluted in the detection buffer. The luminescence signal was  
368 measured with an EnVision plate reader at room temperature.

369

### 370 **Tango assay**

371 Human NTSR1 (1-418) was cloned into pcDNA6 vector consisting of an expression  
372 cassette with tobacco etch virus (TEV) protease cleavage site and the transcriptional  
373 activator tTA at the C terminus. A TEV protease cDNA was fused to the C-terminus of  
374 GRK2 (1-689). Interaction between NTSR1 and GRK2 leads to the cleavage of the  
375 TEV site, thus releasing tTA to trigger tTA-dependent luciferase reporter gene  
376 expression. For Tango assays, HTL cells were cultured in 24-well plate at a density of  
377  $5 \times 10^4$  cells/well for 24 h, and then transfected with 10 ng NTSR1, 10 ng GRK2  
378 plasmids and 5 ng of phRG-tk Renilla luciferase expression plasmids using FuGENE®  
379 HD transfection reagent. After transfection for 24 h, cells were incubated overnight with  
380 PBS (vehicle), or different concentrations of ligands. Then luciferase activities were  
381 evaluated according to manufacturer's protocols of the Dual Luciferase Kit (Promega).

382

### 383 **Acknowledgments**

384 The cryo-EM data were collected at the Advanced Center for Electron Microscopy,  
385 Shanghai Institute of Materia Medica (SIMM). The authors thank the staff at the  
386 Advanced Center for Electron Microscopy for their technical support. This work was  
387 partially supported by Ministry of Science and Technology (China) grants  
388 (2018YFA0507002 to H.E.X.); Shanghai Municipal Science and Technology Major  
389 Project (2019SHZDZX02 to H.E.X.); Shanghai Municipal Science and Technology



390 Major Project (H.E.X.); CAS Strategic Priority Research Program (XDB37030103 to  
391 H.E.X.); the National Natural Science Foundation of China (32130022 to H.E.X.,  
392 32171187 to Y.J., 82121005 to H.E.X. and Y.J.).

393

394 **Author contributions:**

395 J.D. designed the expression constructs, purified the proteins, performed cryo-EM grid  
396 preparation and data collection, participated in functional studies, participated in figure  
397 and manuscript preparation; H.L. performed cryo-EM data calculations, model building,  
398 and participated in figure preparation; Y-J.J participated in protein purification and  
399 functional studies; Q.Y. and K.W. participated in cryo-EM data calculations, X.L., W.Y.,  
400 S.Z., and T.G. participated in the experiments; Y.J. supervised the studies, and  
401 participated in manuscript preparation; H.E.X. and J.D. conceived the project,  
402 analyzed the structures, and wrote the manuscript with inputs from all authors.

403 **References**

- 404 1 Pitcher, J. A., Freedman, N. J. & Lefkowitz, R. J. G protein-coupled receptor kinases. *Annu*  
405 *Rev Biochem* **67**, 653-692, doi:10.1146/annurev.biochem.67.1.653 (1998).
- 406 2 Gurevich, E. V., Tesmer, J. J., Mushegian, A. & Gurevich, V. V. G protein-coupled receptor  
407 kinases: more than just kinases and not only for GPCRs. *Pharmacol Ther* **133**, 40-69,  
408 doi:10.1016/j.pharmthera.2011.08.001 (2012).
- 409 3 Gurevich, V. V. & Gurevich, E. V. GPCR Signaling Regulation: The Role of GRKs and  
410 Arrestins. *Front Pharmacol* **10**, 125, doi:10.3389/fphar.2019.00125 (2019).
- 411 4 Hodavance, S. Y., Gareri, C., Torok, R. D. & Rockman, H. A. G Protein-coupled Receptor  
412 Biased Agonism. *J Cardiovasc Pharmacol* **67**, 193-202,  
413 doi:10.1097/FJC.0000000000000356 (2016).
- 414 5 Rankovic, Z., Brust, T. F. & Bohn, L. M. Biased agonism: An emerging paradigm in GPCR  
415 drug discovery. *Bioorg Med Chem Lett* **26**, 241-250, doi:10.1016/j.bmcl.2015.12.024  
416 (2016).
- 417 6 Seyedabadi, M., Gharghabi, M., Gurevich, E. V. & Gurevich, V. V. Structural basis of GPCR  
418 coupling to distinct signal transducers: implications for biased signaling. *Trends Biochem*  
419 *Sci* **47**, 570-581, doi:10.1016/j.tibs.2022.03.009 (2022).
- 420 7 Slosky, L. M. *et al.* beta-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively  
421 Attenuates Addictive Behaviors. *Cell* **181**, 1364-1379 e1314,  
422 doi:10.1016/j.cell.2020.04.053 (2020).
- 423 8 Benovic, J. L., DeBlasi, A., Stone, W. C., Caron, M. G. & Lefkowitz, R. J. Beta-adrenergic  
424 receptor kinase: primary structure delineates a multigene family. *Science* **246**, 235-240,  
425 doi:10.1126/science.2552582 (1989).
- 426 9 Mushegian, A., Gurevich, V. V. & Gurevich, E. V. The origin and evolution of G protein-  
427 coupled receptor kinases. *PLoS One* **7**, e33806, doi:10.1371/journal.pone.0033806 (2012).
- 428 10 Sulon, S. M. & Benovic, J. L. Targeting G protein-coupled receptor kinases (GRKs) to G  
429 protein-coupled receptors. *Curr Opin Endocr Metab Res* **16**, 56-65,  
430 doi:10.1016/j.coemr.2020.09.002 (2021).
- 431 11 Ribas, C. *et al.* The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in  
432 GPCR regulation and signaling. *Biochim Biophys Acta* **1768**, 913-922,  
433 doi:10.1016/j.bbamem.2006.09.019 (2007).
- 434 12 Beautrait, A. *et al.* Mapping the putative G protein-coupled receptor (GPCR) docking site  
435 on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays. *J Biol*  
436 *Chem* **289**, 25262-25275, doi:10.1074/jbc.M114.593178 (2014).
- 437 13 Baameur, F. *et al.* Role for the regulator of G-protein signaling homology domain of G  
438 protein-coupled receptor kinases 5 and 6 in beta 2-adrenergic receptor and rhodopsin  
439 phosphorylation. *Mol Pharmacol* **77**, 405-415, doi:10.1124/mol.109.058115 (2010).
- 440 14 Komolov, K. E. *et al.* Structural and Functional Analysis of a beta2-Adrenergic Receptor  
441 Complex with GRK5. *Cell* **169**, 407-421 e416, doi:10.1016/j.cell.2017.03.047 (2017).
- 442 15 Lodowski, D. T., Pitcher, J. A., Capel, W. D., Lefkowitz, R. J. & Tesmer, J. J. Keeping G  
443 proteins at bay: a complex between G protein-coupled receptor kinase 2 and  
444 Gbetagamma. *Science* **300**, 1256-1262, doi:10.1126/science.1082348 (2003).
- 445 16 Tesmer, V. M., Kawano, T., Shankaranarayanan, A., Kozasa, T. & Tesmer, J. J. Snapshot of  
446 activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex.

447 *Science* **310**, 1686-1690, doi:10.1126/science.1118890 (2005).

448 17 He, Y. *et al.* Molecular assembly of rhodopsin with G protein-coupled receptor kinases.  
449 *Cell Res* **27**, 728-747, doi:10.1038/cr.2017.72 (2017).

450 18 Chen, Q. *et al.* Structures of rhodopsin in complex with G-protein-coupled receptor kinase  
451 1. *Nature* **595**, 600-605, doi:10.1038/s41586-021-03721-x (2021).

452 19 Rasmussen, S. G. *et al.* Crystal structure of the beta2 adrenergic receptor-Gs protein  
453 complex. *Nature* **477**, 549-555, doi:10.1038/nature10361 (2011).

454 20 Kang, Y. *et al.* Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser.  
455 *Nature* **523**, 561-567, doi:10.1038/nature14656 (2015).

456 21 Zhou, X. E. *et al.* Identification of Phosphorylation Codes for Arrestin Recruitment by G  
457 Protein-Coupled Receptors. *Cell* **170**, 457-469 e413, doi:10.1016/j.cell.2017.07.002 (2017).

458 22 Yin, W. *et al.* A complex structure of arrestin-2 bound to a G protein-coupled receptor.  
459 *Cell Res* **29**, 971-983, doi:10.1038/s41422-019-0256-2 (2019).

460 23 Huang, W. *et al.* Structure of the neurotensin receptor 1 in complex with beta-arrestin 1.  
461 *Nature* **579**, 303-308, doi:10.1038/s41586-020-1953-1 (2020).

462 24 Staus, D. P. *et al.* Structure of the M2 muscarinic receptor-beta-arrestin complex in a lipid  
463 nanodisc. *Nature* **579**, 297-302, doi:10.1038/s41586-020-1954-0 (2020).

464 25 Lee, Y. *et al.* Molecular basis of beta-arrestin coupling to formoterol-bound beta1-  
465 adrenoceptor. *Nature* **583**, 862-866, doi:10.1038/s41586-020-2419-1 (2020).

466 26 Besserer-Offroy, E. *et al.* The signaling signature of the neurotensin type 1 receptor with  
467 endogenous ligands. *Eur J Pharmacol* **805**, 1-13, doi:10.1016/j.ejphar.2017.03.046 (2017).

468 27 Rostene, W. H. & Alexander, M. J. Neurotensin and neuroendocrine regulation. *Front*  
469 *Neuroendocrinol* **18**, 115-173, doi:10.1006/frne.1996.0146 (1997).

470 28 Inagaki, S. *et al.* G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5) Exhibit  
471 Selective Phosphorylation of the Neurotensin Receptor in Vitro. *Biochemistry* **54**, 4320-  
472 4329, doi:10.1021/acs.biochem.5b00285 (2015).

473 29 Kato, H. E. *et al.* Conformational transitions of a neurotensin receptor 1-Gi1 complex.  
474 *Nature* **572**, 80-85, doi:10.1038/s41586-019-1337-6 (2019).

475 30 Barnea, G. *et al.* The genetic design of signaling cascades to record receptor activation.  
476 *Proc Natl Acad Sci U S A* **105**, 64-69, doi:10.1073/pnas.0710487105 (2008).

477 31 Dixon, A. S. *et al.* NanoLuc Complementation Reporter Optimized for Accurate  
478 Measurement of Protein Interactions in Cells. *ACS Chem Biol* **11**, 400-408,  
479 doi:10.1021/acschembio.5b00753 (2016).

480 32 Duan, J. *et al.* Cryo-EM structure of an activated VIP1 receptor-G protein complex  
481 revealed by a NanoBiT tethering strategy. *Nat Commun* **11**, 4121, doi:10.1038/s41467-  
482 020-17933-8 (2020).

483 33 Komolov, K. E., Bhardwaj, A. & Benovic, J. L. Atomic Structure of GRK5 Reveals Distinct  
484 Structural Features Novel for G Protein-coupled Receptor Kinases. *J Biol Chem* **290**,  
485 20629-20647, doi:10.1074/jbc.M115.647297 (2015).

486 34 Draper-Joyce, C. J. *et al.* Positive allosteric mechanisms of adenosine A1 receptor-  
487 mediated analgesia. *Nature* **597**, 571-576, doi:10.1038/s41586-021-03897-2 (2021).

488 35 Egyed, A., Kiss, D. J. & Keseru, G. M. The Impact of the Secondary Binding Pocket on the  
489 Pharmacology of Class A GPCRs. *Front Pharmacol* **13**, 847788,  
490 doi:10.3389/fphar.2022.847788 (2022).

491 36 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion for  
492 improved cryo-electron microscopy. *Nat Methods* **14**, 331-332, doi:10.1038/nmeth.4193  
493 (2017).

494 37 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid  
495 unsupervised cryo-EM structure determination. *Nat Methods* **14**, 290-296,  
496 doi:10.1038/nmeth.4169 (2017).

497 38 Punjani, A. & Fleet, D. J. 3D variability analysis: Resolving continuous flexibility and discrete  
498 heterogeneity from single particle cryo-EM. *J Struct Biol* **213**, 107702,  
499 doi:10.1016/j.jsb.2021.107702 (2021).

500 39 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and  
501 analysis. *J Comput Chem* **25**, 1605-1612, doi:10.1002/jcc.20084 (2004).

502 40 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*  
503 *Crystallogr D Biol Crystallogr* **60**, 2126-2132, doi:10.1107/S0907444904019158 (2004).


504 41 Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution  
505 electron-density maps. *Acta Crystallogr D Struct Biol* **74**, 519-530,  
506 doi:10.1107/S2059798318002425 (2018).

507 42 Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular  
508 structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221,  
509 doi:10.1107/S0907444909052925 (2010).

510 43 Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers, educators,  
511 and developers. *Protein Sci*, doi:10.1002/pro.3943 (2020).


512

Figure 1



**Fig. 1: Cryo-EM structures of the NTSR1-GRK2-Gaq complexes.** **a**, NTS and SBI-553 improve NTSR1-GRK2 interaction determined by Tango assay. RLU, relative Luciferase units. **b**, NTSR1-GRK2 recruitment promoted by addition of NTS and SBI-553 determined by NanoBiT assay. Data were shown as mean  $\pm$  S.E.M. from three independent experiments (n=3), performed in triplicates. The representative concentration-response curves were shown. **c**, **d**, Cryo-EM density maps and ribbon presentation of the NTSR1-GRK2-Gaq complexes. Complex 1 (**c**) and complex 2 (**d**).


Figure 2



**Fig. 2: Structural features of the NTSR1-GRK2-Gaq complex.** **a**, Structural comparison of the NTSR1 from NTSR1-GRK2-Gaq complex with the inactive NTSR1 (PDB code: 7UL2), NTSR1 from NTSR1-arrestin2 complex (PDB code: 6UP7) and NTSR1 from NTSR1-Gi complex (PDB code: 6OS9). **b**, The overall arrangement of the NTS and SBI-

553 binding pockets in NTSR1. **c**, Structural comparison of the NTSR1-GRK2-Gαq complex with the rhodopsin-GRK1 complex (PDB code: 7MTA). KD, kinase domain. PHD, pleckstrin homology domain. RHD, regulatory G-protein signaling homology domain. **d**, Possible membrane binding sites of GRK2 and GRK5. The possible lipid binding sites from GRK2 are highlighted in orange, and the N-terminal lipid binding site (NLBD), the C-terminal lipid binding site (CLBD) of GRK5 (PDB code: 6PJX) are shown in dark red. α9, helix 9. EC, extracellular membrane layer. IC, intracellular membrane layer. The distance between the N-terminal of Gαq with the intracellular membrane layer is around 40 Å, which could be reached by the stretch loop of 38 residues from the N-terminus of Gαq.


Figure 3



**Fig. 3: Interactions between NTSR1 and GRK2. a, b,** Detailed interactions at the major interface between the NTSR1 cytoplasmic hydrophobic pocket and GRK2. **c,** Detailed interactions at the minor interface between the ICL2 from NTSR1 and GRK2. NTSR1 is shown in pink and GRK2 is shown in blue.




Figure 4



**Fig. 4: The binding mode of SBI-553 in NTSR1.** **a**, The EM density of SBI-553, which is shown at a level of 0.12. **b**, **c**, The binding pocket of SBI-553 in NTSR1, from the front view (**b**) and top view (**c**). SBI-553 is highlighted in sphere. **d**, Detailed interactions between SBI-553 and NTSR1, as well as GRK2. SBI-553 is shown in green, NTSR1 is shown in pink, and GRK2 is shown in blue. **e**, Superposition of the NTSR1 from NTSR1-GRK2-Gaq complex and NTSR1-Gi complex showed the  $\alpha 5$  of Gi protein would clash with SBI-553. **f**,


Superposition of the NTSR1 from NTSR1-GRK2-Gαq complex and NTSR1-arrestin complex showed the finger loop of arrestin was compatible with the location of SBI-553.

Figure 5



**Fig. 5: Cartoon presentation of NTSR1 signaling mediated by G protein and arrestin.** NTS promotes NTSR1 to mediate both G protein and arrestin signaling but SBI-553 blocks G protein signaling and promotes GRK2 and arrestin signaling. ++ marks indicate membrane binding.


## Extended Data Figure 1



**Extended Data Fig. 1 NTSR1-GRK2-Gαq complex assembly.** **a**, Screening for GPCR–GRK2 complexes by tango assay. RLU, relative luciferase units, which was normalized to the values of NTSR1. **b–d** SDS-PAGE of the complexes. NTSR1-GRK2-Gαq-Gβγ complex (**b**), NTSR1\_LgBiT-GRK2\_HiBiT-Gαq-Gβγ complex (**c**), NTSR1-GRK2-Gαq complex before crosslinking (left panel of **d**) and NTSR1-GRK2-Gαq complex crosslinked by BS<sub>3</sub> (right panel of **d**). **e**, Size-exclusion chromatography elution profile of the NTSR1-GRK2-Gαq complex. Red star indicates the monomer peak of the complex. **f**, Cryo-EM

micrograph of the NTSR1-GRK2-Gαq complex. Particles picked for 3D classifications were highlighted in red circles.

## Extended Data Figure 2




**Extended Data Fig. 2 Single-particle reconstruction of the NTSR1-GRK2-Gaq complex.** **a**, Flowchart of cryo-EM data analysis of the NTSR1-GRK2-Gaq complex. **b**, Micrograph of the reference-free 2D class averages. **c-e**, Two cryo-EM maps of the NTSR1-GRK2-Gaq complexes were generated and colored by local resolutions from 2.5

Å (blue) to 4.5 Å (purple) (**c and e**). The first map is enlarged for the clarity of SBI-553 and αN of GRK2. SBI-553 and αN of GRK2 are highlighted in red squares (**d**). **f, g**, The “Gold-standard” Fourier shell correlation (FSC) curve indicates that the overall resolution of the electron density map of the NTSR1-GRK2-Gαq complex 1 is 2.92 Å, the NTSR1-GRK2-Gαq complex 2 is 3.09 Å.




### Extended Data Figure 3



**Extended Data Fig. 3 Cryo-EM density maps with all transmembrane helices, and H8 of NTSR1, staurosporine, GDP•Mg<sup>2+</sup>•AlF<sub>4</sub><sup>-</sup> and αN of GRK2.**




## Extended Data Figure 4



**Extended Data Fig. 4 Structural comparison of the NTSR1-GRK2-Gaq complex1 and 2.** Comparison of these two complexes reveals that they have very similar NTSR1 structure but a swing of GRK2 and Gaq of ~5-6 Å related to NTSR1.

## Extended Data Figure 5



**Extended Data Fig. 5 Structural comparison of the GRK2-Gaq from the cryo-EM structure NTSR1-GRK2-Gaq complex with the crystal structure of GRK2-Gaq-G $\beta$  $\gamma$ .** Comparing the GRK2 structure from the NTSR1 complex to the crystal structure of GRK2 from the complex with Gaq and G $\beta$  $\gamma$  reveals three major differences. The GRK2 structure from the NTSR1 complex contains a N-terminal helix that is packed onto the kinase domain, has a breakage in the ionic lock between its RHD from the KD, and adopts a closed conformation in its KD by 2-3 Å shifts of the KD relative to the KD of GRK2 from the crystal structure.




## Extended Data Figure 6



Extended Data Fig. 6 Sequence alignment of human GRKs. The N-terminal helix ( $\alpha$ N) is highlighted in red. The RHD is highlighted in green and KD is in light blue. The AST loop

extended from the kinase domain is in light purple. The PHD of GRK2 and GRK3 are in pink. N-terminal lipid binding domain (NLBD) and C-terminal lipid binding domain (NLBD) according to GRK5 are highlighted in dark yellow and light green, respectively. Residues that may interact with membrane lipid are highlighted in dark blue. And residues from GRK2 that interact with NTSR1 are highlighted in yellow.  $\alpha$ ,  $\alpha$  helix.  $\beta$ ,  $\beta$  strand.


## Extended Data Figure 7



**Extended Data Fig. 7 Structural comparison of NTSR1-GRK2-Gaq complex with NTSR-Gi complex.** Superposition of the NTSR1 from NTSR1-GRK2-Gaq complex and NTSR1-Gi complex showed the  $\alpha 5$  helix from the Gai is up-shift by 8.0 Å into the TMD pocket related to the N-terminal helix of GRK2.



## Extended Data Figure 8



**Extended Data Fig. 8 Structural comparison of NTSR1-GRK2-Gαq complex with NTSR-Gi complex and other GPCR-G protein complexes.** Superposition of the receptors from different GPCR complexes showed that the active GPCRs had very similar 3D architecture, and the location of α5 helix from different G proteins overlapped with the N-terminal helix of GRK2.

Extended Data Table 1 Cryo-EM data collection, refinement and validation statistics.

	NTSR1-GRK2-Gaq complex1 (EMDB-xxxx) (PDB xxxx)	NTSR1-GRK2-Gaq complex2 (EMDB-xxxx) (PDB xxxx)
<b>Data collection and processing</b>		
Magnification		57,477
Voltage (kV)		300
Electron exposure (e-/Å <sup>2</sup> )		50
Defocus range (μm)		-1.2 to -2.2
Pixel size (Å)		0.824
Symmetry imposed		C1
Initial particle images (no.)		40,940,867
Final particle images (no.)	287,853	216,282
Map resolution (Å)	2.92	3.09
FSC threshold	0.143	0.143
Map resolution range (Å)	2.5 – 4.5	2.5 – 4.5
<b>Refinement</b>		
Initial model used (PDB code)	2BCJ, AlphaFold-NTSR1	2BCJ, AlphaFold-NTSR1
Map sharpening <i>B</i> factor (Å <sup>2</sup> )	-103.4	-90.9
Model composition		
Non-hydrogen atoms	10575	10575
Protein residues	1290	1290
Ligands	4	4
Nucleotide	1	1
<b><i>B</i> factors (Å<sup>2</sup>)</b>		
Protein	80.06	80.06
Ligand	47.08	47.08
Nucleotide	76.30	76.30
<b>R.m.s. deviations</b>		
Bond lengths (Å)	0.005	0.005
Bond angles (°)	0.989	0.989
<b>Validation</b>		
MolProbity score	1.77	1.83
Clashscore	4.23	4.94
Poor rotamers (%)	0.00	0.00
<b>Ramachandran plot</b>		
Favored (%)	94.99	95.07
Allowed (%)	5.01	4.93
Disallowed (%)	0.00	0.00

**Extended Data Table 2 Interactions of SBI-553 with NTSR1 and GRK2**

SBI-553	V101 <sup>2.39</sup>	NTSR1
	H102 <sup>2.40</sup>	
	V159 <sup>3.43</sup>	
	L162 <sup>3.46</sup>	
	R166 <sup>3.50</sup>	
	I170 <sup>3.54</sup>	
	N256 <sup>5.58</sup>	
	I259 <sup>5.61</sup>	
	L305 <sup>6.37</sup>	
	V308 <sup>6.40</sup>	
	N360 <sup>7.49</sup>	
	Y364 <sup>7.53</sup>	
	V367 <sup>7.56</sup>	
	S368 <sup>8.47</sup>	
	F371 <sup>8.50</sup>	
	L4	
E5		
L8		



## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ExtendedDataMovie.mp4](#)